Format

Send to

Choose Destination
Nat Rev Cancer. 2003 Jan;3(1):46-54.

Validating survivin as a cancer therapeutic target.

Author information

1
Department of Cancer Biology, LRB-428, University of Massachusetts Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, USA. dario.altieri@umassmed.edu

Abstract

Acquisition of the ability to evade cellular suicide, or apoptosis, is one of the master switches that contributes to cellular transformation and, ultimately, to invasive cancer. Much has been learned about the molecular organization of apoptotic pathways and their regulators, but the identification and validation of translational targets for apoptosis-based cancer therapy has posed a great challenge. Survivin is an attractive candidate for cancer therapy, so what is its potential applicability in the clinic?

PMID:
12509766
DOI:
10.1038/nrc968
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center